Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomepromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomepromazine SCHEMBL8762418 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29508092 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL25462 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL30411640 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29425180 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL23859840 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL6944555 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL418079 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29846205 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL1611636 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118510519-A | Specific doses of phenothiazine compounds for use in the treatment or prevention of Alzheimer's dementia | 免疫基因股份公司 | 2024-08-16 | — | — | CN | claimed |
| CN-117915901-A | Combined administration method of deutetrabenazine and CYP2D6 inhibitor | 纽罗克里生物科学有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117642165-A | Valphenazine for the additional treatment of schizophrenia | 纽罗克里生物科学有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-110691794-B | anti-IGF-I receptor antibodies | 帝人制药株式会社 | 2023-10-27 | — | — | CN | claimed |
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | GSKB Pharmaceuticals, LLC | 2025-07-31 | — | — | US | disclosed |
| CN-115667235-B | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | 卡鲁娜治疗学有限公司 | 2025-06-17 | — | — | CN | disclosed |
| CN-110573184-B | RNA nanostructures, methods of making and uses thereof | 俄亥俄州立创新基金会 | 2025-05-13 | — | — | CN | disclosed |
| CN-119707853-A | Phenoxazine derivative and preparation method and application thereof | 中国科学技术大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-119654149-A | Subcutaneous administration and dosing method of olanzapine for use in the treatment of depressive disorders | 诺华股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-112566894-B | Potent inhibitors of D-amino acid oxidase (DAAO) and uses thereof | 心悦生医股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-113286612-B | Humanized antibodies against IGF-I receptor | 帝人制药株式会社 | 2024-12-24 | — | — | CN | disclosed |
| CN-119156202-A | Comprises atecarpone blue composition | 杨森制药公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-114729384-A | Engineered adeno-associated virus capsids | 博德研究所 | 2022-07-08 | — | — | CN | disclosed |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | ALK-ABELLÓ, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| CN-114585746-A | Method for evaluating toxicity of drug | 公立大学法人横滨市立大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-112365989-B | Equivalent signal mining method for SRS combined adverse reaction signals | 长沙市弘源心血管健康研究院 | 2022-05-03 | — | — | CN | disclosed |
| CN-112390799-B | Nitrogen-containing heterocyclic 5-HT3 receptor regulator and preparation method and application thereof | 科岭源生物科技(深圳)有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114286674-A | Esketamine for use in the treatment of patients with major depressive disorder including suicidal ideation | 杨森制药公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114126595-A | Esketamine for the treatment of depression | 杨森制药公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTC, OAT, MYOC | DRD3 4294/4885DRD2 4404/4885DRD4 4627/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | DRD3 4814/4885DRD2 4742/4885DRD4 4871/4885 |
| US-20250241910-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PSYCHIATRIC DISORDER | SLC6A4, SLC6A2, SLC6A3 | DRD3 74/4885DRD2 18/4885DRD4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.